Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus S-1 or capecitabine as adjuvant therapy after curative surgery for high-risk biliary tract cancer
ChiCTR2600132074Phase 4Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Mar 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab, tegafur and capecitabine in biliary cancer, sponsored by Shandong Cancer Hospital. Primary endpoint: 2-year disease-free survival rate. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
camrelizumabtegafurcapecitabine
03
Conditions
biliary cancer
Beyond the preview
Go deeper on ChiCTR2600132074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132074.